KB-1120

BMS986340-hIgG1-DLE

Background

BMS-986340, a novel anti-CCR8 NF monoclonal antibody in development, led to measurable CCR8+ Treg depletion in human tumor explants. CCR8+ Treg depletion led to robust antitumor activity alone and in combination with anti-PD-1 in mouse tumor models. These results support further clinical evaluation of CCR8 depletion in combination with immune checkpoint blockade as a novel immunotherapy for cancer.

Specifications

Catalog Number:
KB-1120
Cell Line Name:
BMS986340-hIgG1-DLE
Price:
0
Host Cell Line:
EXPI-CHO
Target:
CCR8
Species Reactivity:
Human
Application:
FACS
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | FACS

References

1.PB Silver, et al., Retina-specific T regulatory cells bring about resolution and maintain remission of autoimmune uveitis. J Immunol 194, 3011–3019 (2015). 2.J van Loosdregt, et al., Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity. Immunity 39, 259–271 (2013).
Please enable JavaScript in your browser to complete this form.